Complex of angiotensin receptor antagonist and neutral endopeptidase inhibitor

US10537555B2 · kind B2 · utility

Assignee

• Chengdu Easton Biopharmaceuticals Co., Ltd. · CN

Inventors

• Ying Wang · Chengdu, CN
• Long Huang · Chengdu, CN
• Yongzhe Xiang · Chengdu, CN
• Guodong Cen · Sichuan, CN
• Jianguo Li · Beijing, CN
• Jianjing Jia · Chengdu, CN
• Qiangqiang Liu · Chengdu, CN
• Yang Liu · Columbus, US
• Haitao Yang · Nanhu, CN
• Qing Dong · San Diego, US

Key dates

• Filing date: Sep 1, 2016
• Grant date: Jan 21, 2020
• Expiry date: Sep 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D257/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided a complex of formula is [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3′-methyl-2′-(pentanoyl {2″-(tetrazol-5-ylate) biphenyl-4′-ylmethyl}amino) butyrate]6.XCa2+.YNa+.ZH2O, wherein X=1-3, Y=12-16, Z=9-18, and 2X+Y=18, and represented by formula (I). Also disclosed are the method of preparing the complex and the method of treating chronic heart disease using a medicament comprising the complex.